Logo image of ANGN

ANGION BIOMEDICA CORP (ANGN) Stock Fundamental Analysis

NASDAQ:ANGN - Nasdaq - US03476J1079 - Common Stock - Currency: USD

1  +0.02 (+2.04%)

After market: 0.9437 -0.06 (-5.63%)

Fundamental Rating

3

ANGN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. ANGN has a great financial health rating, but its profitability evaluates not so good. ANGN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ANGN had negative earnings in the past year.
In the past year ANGN has reported a negative cash flow from operations.
ANGN had negative earnings in each of the past 5 years.
In the past 5 years ANGN always reported negative operating cash flow.
ANGN Yearly Net Income VS EBIT VS OCF VS FCFANGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 -20M -40M -60M -80M

1.2 Ratios

The profitability ratios for ANGN are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ANGN Yearly ROA, ROE, ROICANGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 0 200 -200 400

1.3 Margins

With an excellent Gross Margin value of 352.37%, ANGN belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
In the last couple of years the Gross Margin of ANGN has grown nicely.
ANGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 352.37%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.57%
GM growth 5YN/A
ANGN Yearly Profit, Operating, Gross MarginsANGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 0 -500 -1K -1.5K -2K -2.5K

More info and screens

7

2. Health

2.1 Basic Checks

ANGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ANGN has been increased compared to 1 year ago.
The debt/assets ratio for ANGN is higher compared to a year ago.
ANGN Yearly Shares OutstandingANGN Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 10M 20M 30M
ANGN Yearly Total Debt VS Total AssetsANGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -0.82, we must say that ANGN is in the distress zone and has some risk of bankruptcy.
ANGN has a Altman-Z score (-0.82) which is comparable to the rest of the industry.
ANGN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.82
ROIC/WACCN/A
WACC8.33%
ANGN Yearly LT Debt VS Equity VS FCFANGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 0 50M -50M

2.3 Liquidity

ANGN has a Current Ratio of 20.00. This indicates that ANGN is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 20.00, ANGN belongs to the best of the industry, outperforming 92.13% of the companies in the same industry.
A Quick Ratio of 20.00 indicates that ANGN has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 20.00, ANGN belongs to the best of the industry, outperforming 92.13% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 20
Quick Ratio 20
ANGN Yearly Current Assets VS Current LiabilitesANGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 38.28% over the past year.
ANGN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -97.79%.
The Revenue has been growing by 15.59% on average over the past years. This is quite good.
EPS 1Y (TTM)38.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.3%
Revenue 1Y (TTM)-97.79%
Revenue growth 3Y15.59%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

ANGN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.22% yearly.
The Revenue is expected to decrease by -25.99% on average over the next years. This is quite bad
EPS Next Y34.37%
EPS Next 2Y25.74%
EPS Next 3Y18.22%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ANGN Yearly Revenue VS EstimatesANGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 5M 10M 15M 20M 25M
ANGN Yearly EPS VS EstimatesANGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 -1 -2 -3 -4 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ANGN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ANGN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANGN Price Earnings VS Forward Price EarningsANGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANGN Per share dataANGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as ANGN's earnings are expected to grow with 18.22% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.74%
EPS Next 3Y18.22%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ANGN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANGION BIOMEDICA CORP

NASDAQ:ANGN (6/1/2023, 8:00:00 PM)

After market: 0.9437 -0.06 (-5.63%)

1

+0.02 (+2.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-10 2023-05-10
Earnings (Next)08-14 2023-08-14
Inst Owners10.12%
Inst Owner Change-31.79%
Ins Owners16.95%
Ins Owner Change0%
Market Cap30.11M
Analysts43.33
Price Target1.53 (53%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.96%
Min EPS beat(2)1.96%
Max EPS beat(2)1.96%
EPS beat(4)3
Avg EPS beat(4)18.93%
Min EPS beat(4)1.96%
Max EPS beat(4)36.52%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 46.12
P/FCF N/A
P/OCF N/A
P/B 0.76
P/tB 0.76
EV/EBITDA N/A
EPS(TTM)-1.29
EYN/A
EPS(NY)-0.54
Fwd EYN/A
FCF(TTM)-1.02
FCFYN/A
OCF(TTM)-1.02
OCFYN/A
SpS0.02
BVpS1.32
TBVpS1.32
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 352.37%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.57%
GM growth 5YN/A
F-Score3
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 20
Quick Ratio 20
Altman-Z -0.82
F-Score3
WACC8.33%
ROIC/WACCN/A
Cap/Depr(3y)153.26%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)38.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.3%
EPS Next Y34.37%
EPS Next 2Y25.74%
EPS Next 3Y18.22%
EPS Next 5YN/A
Revenue 1Y (TTM)-97.79%
Revenue growth 3Y15.59%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
EBIT growth 1Y29.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.16%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y27.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.07%
OCF growth 3YN/A
OCF growth 5YN/A